Drug Trial Radar · NCT00782340
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Last checked: Nov 20, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
263
Actual
Start
Sep 2008
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Chelsea TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Chiltern International Inc.
- First posted
- Oct 31, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Non-diabetic Neuropathy
- Primary Autonomic Failure
- Dopamine Beta Hydroxylase Deficiency
Interventions
PlaceboDrug
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
DroxidopaDrug
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Orthostatic Hypotension Questionnaire Score (OHQ)Time frame: 7 days
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
North Alabama Neuroscience
Huntsville, Alabama
Mayo Clinic-Arizona
Scottsdale, Arizona
Arkansas Cardiology
Little Rock, Arkansas
University of California, Irvine
Irvine, California
Bradenton Neurology, Inc
Bradenton, Florida
Suncoast Neuroscience Associates, Inc
St. Petersburg, Florida
University of Kansas Medical Center
Kansas City, Kansas
Cncs, Ninds,Nih
Bethesda, Maryland
Nerological Reserch Center at Hattiesburg
Hattiesburg, Mississippi
North Shore Hospital
Manshasette, New York
Pennsylvania Hospital of the University of PA Health System- Department of Neurology
Philadelphia, Pennsylvania
HAN Neurological Associates
Upland, Pennsylvania
Baylor College of Medicine
Houston, Texas
Evergreen Hospital Medical Center; Booth Gardner Parkinson's Care Center
Kirkland, Washington
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Movment Disorder Clinic Deer lodge Centre
Winnipeg, Manitoba, Canada
David B. King, - Private Clinic
Halifax, Nova Scotia, Canada
London Health Sciences Centre, UH
London, Ontario, Canada
UHNresearch
Toronto, Ontario, Canada
IRCM
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.